TET2 and pulmonary arterial hypertension: The major novel finding of this study is the existence of a pan‐chromosomal hypermethylation signature in PAH patients, which is more pronounced in those carrying TET2 mutations, as would be predicted with a loss of TET2's demethylation function associated with the loss of function mutations previously noted in these patients (Potus et al. 2020).